Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDIntellia Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 7 | -$1.45 | -$1.15 | -$1.34 |
| Q2 2025 | 3 | -$2.37 | -$0.53 | -$1.30 |
| Q3 2025 | 6 | -$2.34 | -$0.52 | -$1.29 |
| Q4 2025 | 5 | -$2.27 | -$0.51 | -$1.25 |
| Q1 2026 | 4 | -$1.98 | -$0.44 | -$1.09 |
| Q2 2026 | 3 | -$2.04 | -$0.46 | -$1.12 |
| Q3 2026 | 2 | -$2.16 | -$0.48 | -$1.19 |
| Q4 2026 | 2 | -$2.25 | -$0.50 | -$1.24 |
Intellia Therapeutics, Inc. Earnings Date And Information
Intellia Therapeutics, Inc. last posted its earnings results on Thursday, November 7th, 2024. The company reported $-1.34 earnings per share for the quarter, topping analysts' consensus estimates of $-1.37 by $0.03. The company had revenue of 9.11 M for the quarter and had revenue of 36.28 M for the year. Intellia Therapeutics, Inc. has generated $-5 earnings per share over the last year ($-5.42 diluted earnings per share) and currently has a price-to-earnings ratio of -1.88. Intellia Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 20th, 2025 based on prior year's report dates.
Intellia Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/07/2024 | Q3 2024 | -$1.37 | -$1.34 | 0.03 | $8.28 M | $9.11 M |
| 08/08/2024 | Q2 2024 | -$1.21 | -$1.52 | -0.31 | $19.68 M | $6.96 M |
| 05/09/2024 | Q1 2024 | -$1.35 | -$1.12 | 0.23 | $28.94 M | |
| 02/22/2024 | Q4 2023 | -$1.47 | -$1.46 | 0.01 | $-1,917,000 | |
| 11/09/2023 | Q3 2023 | -$1.52 | -$1.38 | 0.14 | $13.05 M | $11.99 M |
| 08/03/2023 | Q2 2023 | -$1.32 | -$1.40 | -0.08 | $12.08 M | $13.59 M |
| 05/04/2023 | Q1 2023 | -$1.41 | -$1.05 | 0.36 | $12.61 M | |
| 02/23/2023 | Q4 2022 | -$1.40 | -$1.44 | -0.04 | $13.57 M | |
| 11/03/2022 | Q3 2022 | -$1.31 | -$1.49 | -0.18 | $11.89 M | $13.27 M |
| 08/04/2022 | Q2 2022 | -$1.31 | -$1.32 | -0.01 | $9.42 M | $14.03 M |
| 05/05/2022 | Q1 2022 | -$1.11 | -$1.96 | -0.85 | $11.25 M | |
| 02/24/2022 | Q4 2021 | -$0.91 | -$1.09 | -0.18 | $12.85 M | |
| 11/04/2021 | Q3 2021 | -$0.85 | -$0.97 | -0.12 | $8.66 M | $7.20 M |
| 08/05/2021 | Q2 2021 | -$0.61 | -$1.01 | -0.4 | $12.21 M | $6.55 M |
| 05/06/2021 | Q1 2021 | -$0.66 | -$0.69 | -0.03 | $6.45 M | |
| 02/25/2021 | Q4 2020 | -$0.69 | $6.60 M | |||
| 11/05/2020 | Q3 2020 | -$0.54 | -$0.47 | 0.07 | $14.90 M | $22.22 M |
| 08/06/2020 | Q2 2020 | -$0.69 | -$0.61 | 0.08 | $9.53 M | $16.26 M |
| 05/07/2020 | Q1 2020 | -$0.39 | -$0.63 | -0.24 | $12.92 M | |
| 02/27/2020 | Q4 2019 | -$0.54 | -$0.57 | -0.03 | $10.94 M |
Intellia Therapeutics, Inc. Earnings: FAQ's
When is Intellia Therapeutics, Inc.'s earnings date?
Intellia Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 20th, 2025 based off last year's report dates.
Did Intellia Therapeutics, Inc. beat their earnings estimates last
quarter?
In the previous quarter, Intellia Therapeutics, Inc. (:NTLA) reported $-1.34 earnings per share (EPS) to beat the analysts' consensus estimate of $-1.37 by $0.03.
How can I listen to Intellia Therapeutics, Inc.'s earnings conference
call?
The conference call for Intellia Therapeutics, Inc.'s latest earnings report can be listened to online.
How can I read Intellia Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Intellia Therapeutics, Inc.'s latest earnings report can be read online.
How much revenue does Intellia Therapeutics, Inc. generate each year?
Intellia Therapeutics, Inc. (:NTLA) has a recorded annual revenue of $36.28 M.
How much profit does Intellia Therapeutics, Inc. generate each year?
Intellia Therapeutics, Inc. (:NTLA) has a recorded net income of $36.28 M. Intellia Therapeutics, Inc. has generated $-5.42 earnings per share over the last four quarters.
What is Intellia Therapeutics, Inc.'s price-to-earnings ratio?
Intellia Therapeutics, Inc. (:NTLA) has a price-to-earnings ratio of -1.88 and price/earnings-to-growth ratio is -2.58.